Advanced search
Publication Cover
Leukemia & Lymphoma Volume 64, 2023 - Issue 1
Submit an article Journal homepage
305
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Frontline treatment approaches in TP53-aberrant mantle cell lymphoma

Nikesh N. Shaha Department of Hematology and Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USAORCID Iconhttps://orcid.org/0000-0002-7558-9222View further author information
ORCID Icon,
Franco Castillo-Tokumorib Department of Internal Medicine, University of South Florida, Tampa, FL, USAView further author information
,
Junmin Whitingc Department of Biostatistics & Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USAView further author information
,
David Boulwarec Department of Biostatistics & Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USAView further author information
,
Jose Sandoval-Susd Department of Malignant Hematology and Cellular Therapy at Memorial Healthcare System, Moffitt Cancer Center, Pembroke Pines, FL, USAView further author information
,
Todd C. Kneppere Department of Individualized Cancer Management, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USAView further author information
,
Mohammad Hussainif Department of Pathology, H. Lee Moffitt Cancer, Tampa, FL, USAView further author information
,
Jianguo Taof Department of Pathology, H. Lee Moffitt Cancer, Tampa, FL, USAView further author information
,
Julio C. Chavezg Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USAView further author information
,
Leidy Isenalumheg Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USAView further author information
,
Sameh Gaballag Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USAView further author information
,
Hayder Saeedg Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USAView further author information
,
Celeste Bellog Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USAView further author information
,
Lubomir Sokolg Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USAView further author information
,
Javier Pinilla-Ibarzg Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USAView further author information
&
Bijal D. Shahg Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-4328-6021View further author information
ORCID Icon show all
Pages 230-233 | Received 26 Jul 2021, Accepted 18 Sep 2022, Published online: 27 Oct 2022

References

  • Cohen JB, Han X, Jemal A, et al. Deferred therapy is associated with improved overall survival in patients with newly diagnosed mantle cell lymphoma. Cancer. 2016;122(15):2356–2363.
  • Martin P, Chadburn A, Christos P, et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol. 2009;27(8):1209–1213.
  • Delarue R, Haioun C, Ribrag V, et al. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the groupe d‘Etude des lymphomes de l‘Adulte. Blood. 2013;121(1):48–53.
  • Geisler CH, Kolstad A, Laurell A, et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood. 2008;112(7):2687–2693.
  • Ruan JM, Christos P, Cerchietti L, et al. Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma. Blood. 2018;132(19):2016–2025.
  • Yamshon S, Martin P, Shah B, et al. Initial treatment with lenalidomide plus rituximab for mantle cell lymphoma (MCL): 7-year analysis from a multi-center phase II study. Blood. 2020;136(Supplement 1):45–46.
  • Ruan J, Martin P, Shah B, et al. Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma. N Engl J Med. 2015;373(19):1835–1844.
  • Eskelund CW, Dahl C, Hansen JW, et al. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood. 2017;130(17):1903–1910.
  • Delfau-Larue MH, Klapper W, Berger F, et al. High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma. Blood. 2015;126(5):604–611.
  • Aukema SM, Hoster E, Rosenwald A, et al. Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network. Blood. 2018;131(4):417–420.
  • LaCasce AS, Vandergrift JL, Rodriguez MA, et al. Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL database. Blood. 2012;119(9):2093–2099.
  • Eskelund CW, Albertsson-Lindblad A, Kolstad A, et al. Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma. Haematologica. 2018;103(11):e541–e543.
  • Fecteau JF, Corral LG, Ghia EM, et al. Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21(WAF1/Cip1)-dependent mechanism independent of functional p53. Blood. 2014;124(10):1637–1644.
  • Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382(14):1331–1342.
  • Jerkeman M, Eskelund CW, Hutchings M, et al. Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial. Lancet Haematol. 2018;5(3):e109–e116.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.